CBUS
Cibus, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.17
+2.19%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.18
From 52W high−71.23%
Volume56587.00
Market cap$89.04M
P/E (TTM)—
P/S (TTM)20.5x
Div yield—
Key dataNov 4, 2026
Open
$1.18
From 52W high
−71.23%
Volume
56587.00
Market cap
$89.04M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
29.7
MomentumView details →
1D Return
+2.19%
YTD Return
−33.33%
SummaryUpdated Jun 1, 2026
Cibus, Inc. (NASDAQ:CBUS) is a San Diego-based agricultural biotechnology company founded in 2001 that develops gene-edited plant traits for licensing to seed companies. The company went public in July 2017 and has evolved from a research-focused organization into a commercial gene editing platform. Cibus specializes in developing productivity traits that help farmers achieve higher yields while reducing chemical inputs, as well as sustainable ingredients that can replace fossil fuel-based components in various products.
Similar companies
Latest newsMore news →
Cibus announced that it will report its third-quarter 2026 financial results on November 12, 2026, after the market close, and host a conference call and webcast at 4:30 p.m. ET.22h agoCibus and Crystal Crop Protection announced a collaboration to improve mustard crop varieties in India using Cibus' gene-editing platform and Crystal Crop's mustard germplasm and distribution reach.37d ago